Keywords: bayer, reports, further, riociguat, data, ats, positive

Bayer reports further riociguat data at ATS

Article | 03 June 2009

Print This

Positive data from a Phase II trial with German drug major Bayer Schering Pharma's oral agent riociguat in chronic thromboembolic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in